Business Wire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...
Hoodline

SF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir Makeover

After a flop, Vir pivoted from flu to cancer under Marianne De Backer — closing labs, cutting staff and landing big deals.

Vir Biotechnology Announces Board Changes and Shareholder Approvals

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings.
Business Wire

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and ...

How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story

Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Finanznachrichten

Vir Biotechnology, Inc.: Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell ...